Download Files:
Products Details
Product Description
– Tofogliflozin (CSG-452) is a highly efficient and selective inhibitor of SGLT2, with Ki values of 2.9, 14.9 and 6.4nM for human, rat and mouse SGLT2 respectively.
Web ID
– HY-14902
Shipping
– Room temperature
Applications
– Metabolism-sugar/lipid metabolism
Molecular Formula
– C22H26O6
Citations
– Biochem Pharmacol. 2016 Feb 1;101:27-39. |J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Mar 15;1141:122020.|Biochem Pharmacol. 2018 Jun;152:45-59.
References
– [1]Nagata T, et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol. 2013 Oct;170(3):519-31.|[2]Yamane M, et al. In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP. Xenobiotica. 2014 Oct 28:1-9.|[3]Suzuki M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012 Jun;341(3):692-701.|[4]Nagata T, et al. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. Am J Physiol Endocrinol Metab. 2013 Feb 15;304(4):E414-23.
CAS Number
– 903565-83-3
Molecular Weight
– 386.44
SMILES
– O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@]21OCC3=CC=C(CC4=CC=C(CC)C=C4)C=C23
Clinical Information
– Launched
Research Area
– Metabolic Disease
Solubility
– 10 mM in DMSO
Target
– SGLT
Isoform
– SGLT2
Pathway
– Membrane Transporter/Ion Channel
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
